£1m Funding for Innovative Drug Discovery Projects in Collaboration with Medicines Discovery Catapult
Two groundbreaking drug discovery projects, supported by Medicines Discovery Catapult (MDC), have secured over £1m in funding from Innovate UK's Launchpad Northern Ireland programme.
SignaCor Therapeutics and Klas Therapeutics, both based in Northern Ireland, have been awarded a share of funding from the Launchpad programme.
The funding provides a vital boost to the SMEs' research programmes, which focus on innovations to treat heart disease and skin cancer.